LifeMD Reports Second Quarter 2026 Results
LifeMD, Inc. (LFMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LifeMD Reports Second Quarter 2026 Results ● Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of approximately $3.5 million, improving approximately 21% sequentially. ● Approximately
How this was made
The 30-second read
Why it matters
The filing provides fresh Q2 operating results and a revised full-year 2026 outlook, including a quantified path to positive adjusted EBITDA in 2H26 and an exit revenue run rate target for Q4.
Market read
Traders can update models immediately using the revised FY2026 revenue and adjusted EBITDA ranges, plus Q2 margin, subscriber, and cash/liquidity metrics.
What to watch
The article notes profitability headwinds from the branded GLP-1 transition and lower upfront cash collection; traders may underweight how quickly recurring rebill and longer-duration packages translate into cash flow.
Background
This is an SEC Form 8-K (Item 2.02) with an attached earnings release for LifeMD’s second quarter ended June 30, 2026.
Ticker impact
LifeMD reported Q2 2026 revenue of $47.3M, gross margin near 89%, and revised FY2026 guidance to revenue $205.5M-$212.5M and adjusted EBITDA loss to breakeven.
Likely supportive for the stock on guidance credibility and margin/subscriber momentum, but tempered by the still-negative adjusted EBITDA range for FY2026.
The filing is a primary disclosure with multiple decision-relevant datapoints: Q2 results vs guidance, a clear transition away from compounded GLP-1, cash/no-debt position, and a quantified FY2026 guidance reset tied to XYOSTED launch costs and 2H26 profitability timing.
Market effects
Reinforces the competitive shift in weight management from compounded GLP-1 to branded therapies and highlights margin sensitivity to fulfillment and in-house pharmacy scaling.
No clear regional spillover beyond US-listed virtual care and pharmacy services sentiment.
Limited, as the disclosure is company-specific and US-focused (FDA-approved XYOSTED and US subscriber metrics).
Counterpoint
The guidance revision still implies adjusted EBITDA is negative through most of 2026, so the market may focus on execution risk around XYOSTED launch costs and sustained subscriber retention.
Key entities
- companyLifeMD, Inc.
Virtual primary care and pharmacy services provider reporting Q2 2026 results and revising FY2026 guidance.
- partnerHalozyme’s wholly-owned subsidiary, Antares Pharma, Inc.
Co-marketing collaboration partner for XYOSTED® referenced in the release.
- productXYOSTED®
FDA-approved once-weekly subcutaneous testosterone auto-injector launched via the collaboration.
